PMID

Data

Article Title

Organization

The discovery of N-((2H-tetrazol-5-yl)methyl)-4-((R)-1-((5r,8R)-8-(tert-butyl)-3-(3,5-dichlorophenyl)-2-oxo-1,4-diazaspiro[4.5]dec-3-en-1-yl)-4,4-dimethylpentyl)benzamide (SCH 900822): a potent and selective glucagon receptor antagonist.

Merck Research Laboratories

Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-ß-alanine (MK-0893) for the treatment of type II diabetes.

Merck Research Laboratories

Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core.

Merck Research Laboratories

A novel long-acting oxyntomodulin analogue eliminates diabetes and obesity in mice.

Beijing University of Chinese Medicine

Optimization of Truncated Glucagon Peptides to Achieve Selective, High Potency, Full Antagonists.

Indiana University

Potent, orally absorbed glucagon receptor antagonists.

Merck Research Laboratories

Optimization of peptide-based polyagonists for treatment of diabetes and obesity.

Novo Nordisk Research Center Indianapolis

Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists.

Sanofi-Aventis Deutschland